Meditation enhances brain oxygenation, upregulates BDNF and improves quality of life in patients with primary open angle glaucoma: A randomized controlled trial
Background: Glaucoma (POAG) is a kind of neurodegenerative disease known to be closely associated with stress and adverse quality of life (QOL). Stress has also been shown to be involved in etiopathogenesis of primary open angle glaucoma (POAG). Complementary treatment in form of Meditation has been...
Saved in:
Published in | Restorative neurology and neuroscience Vol. 36; no. 6; pp. 741 - 753 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London, England
SAGE Publications
01.01.2018
Sage Publications Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background:
Glaucoma (POAG) is a kind of neurodegenerative disease known to be closely associated
with stress and adverse quality of life (QOL). Stress has also been shown to be involved
in etiopathogenesis of primary open angle glaucoma (POAG). Complementary treatment in
form of Meditation has been reported to improve QOL, brain oxygenation and decrease
markers of stress. With this premise, a randomized controlled trial was carried out to
assess the effect of Meditation on intraocular pressure, subjective QOL and objective
markers of stress and brain oxygenation in patients with POAG.
Methods:
Sixty patients were randomized into intervention and control groups. Intervention group
underwent 45 minutes of Meditation daily for 6 weeks in addition to standard medical
treatment while controls received only standard medical treatment. Inclusion criteria
were patients with POAG, age >45 years, best corrected visual acuity >6/60.
Patients with other ocular co-morbid conditions contributing to vision loss, systemic
diseases, patients already practicing meditation in any form were excluded. An
assessment of IOP, brain oxygenation using functional near infrared spectroscopy
(fNIRS), QOL (WHO-BREF QOL) and stress markers in serum (cortisol, β-endorphins,
interleukin-6, brain derived neurotrophic factor (BDNF), reactive oxygen species) was
made at baseline and at 6 weeks.
Results:
21 female and 39 male patients were enrolled with a mean age of 57.28±9.37 years. All
parameters were comparable between two groups at baseline. At 6 weeks mean level of IOP
decreased significantly in intervention group (15.9±1.8 mmHg to 14.4±1.21 mm Hg,
p-value 0.0001) as compared to control group (15.7±1.4 mmHg to
15.65±1.41, p-value 0.41). fNIRS showed significant improvement in
oxygenated hemoglobin change (ΔHbO) in intervention group in the
prefrontal cortex (p-value < 0.0001) as compared to control group
(p-value 0.52). WHO-BREF QOL score increased significantly in
intervention group (86.6±6.16 to 93.3±5.66, p-value 0.0001) as compared
to control (89±7.25 to 89.07±3.24, p-value 0.74).Mean serum cortisol
decreased significantly in intervention group (497±46.37 ng/ml to 447±53.78 ng/ml,
p-value 0.01) as compared to control group (519.75±24.5 to
522.58±26.63 ng/ml, p-value 0.64). Mean β-endorphin levels increased
significantly (33±5.52pg/ml to 43.27pg/ml, p-value < 0.0001) as
compared to control group (34.78±4.1pg/ml to 36.33pg±4.07pg/ml p-value
0.27). Interleukin-6 decreased significantly in intervention group (2.2±0.5 ng/ml to
1.35±0.32 ng/ml, p-value < 0.0001) as compared to control group
(2.03±0.37 to 2.17±0.34 ng/ml p-value 0.25). BDNF increased
significantly in intervention group (52.24±6.71 to 63.25±13.48 ng/ml
p-value 0.004) as compared to control group (53.23±5.82 to
54.42±5.66 ng/ml p-value 0.54). ROS decreased significantly in
intervention group (1596.19±179.14 to 1261±244.31 RLU/min/104 neutrophils
p-value 0.0001) as compared to control group (1577.5±172.02 to
1662.5±84.75 RLU/min/104 neutrophils p-value 0.16).
Conclusions:
A short term course of Meditation was associated with significant improvement in brain
oxygenation and QOL along with a reduction in IOP and stress markers. Meditation may be
a useful as an adjunct to standard treatment in patients with POAG and potentially
decrease the risk of glaucoma progression. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
ISSN: | 0922-6028 1878-3627 1878-3627 |
DOI: | 10.3233/RNN-180857 |